News | November 01, 2006

Homegrown EHRs Can Get Certified

The Certification Commission for Healthcare Information Technology is inviting organizations to submit their ambulatory electronic health-record products for possible certification during the next application period, running Nov. 1-14. The application period marks the launch of CCHIT certification of ambulatory EHRs internally developed by physician practices, hospitals and health systems.

The names of products receiving certification during this period are tentatively scheduled to be announced Feb. 1.

These systems will be evaluated using the same test script and functionality, security and interoperability criteria as commercial EHRs. To date, CCHIT has certified 35 ambulatory EHRs. While CCHIT posts the names of the certified products on its Web site, www.cchit.org, it doesn’t reveal the names of products that didn’t pass its inspection and failed to receive a 100% score on its 200-item test. Vendors must submit a $28,000 fee to have their products tested.

CCHIT was awarded a $2.7 million HHS contract last September to develop a sustainable process to certify health IT products first for the outpatient setting, and then for inpatient and hospital EHRs. CCHIT was created in 2004 by three Chicago-based organizations: the American Health Information Management Association, the Healthcare Information and Management Systems Society and the National Alliance for Health Information Technology.

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init